Optimal lipofection reagent varies with the molecular modifications of the DNA

Antisense and Nucleic Acid Drug Development

Volumn 8, Issue 5, 1998, Pages 427-434

  Conrad, Abigail H ^a   Behlke, Mark A ^b   Jaffredo, Thierry ^c   Conrad, Gary W ^a  

^a KANSAS STATE UNIVERSITY   (United States)

^b INTEGRATED DNA TECHNOLOGIES   (United States)

^c l'alimentation et l'Environnement   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCEIN; LIPID;

ANIMAL CELL; ARTICLE; CELL TYPE; DNA MODIFICATION; DNA TRANSFECTION; FLUORESCENCE; GENE EXPRESSION; HEART MUSCLE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; QUAIL;

EID: 0031739308     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1998.8.427     Document Type: Article

References (13)

1. AGRAWAL, S., JIANG, Z., ZHAO, Q., SHAW, D., CAI, Q., ROSKEY, A., CHANNAVAJJALA, L., SAXINGER, C., and ZHANG, R. (1997). Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc. Natl. Acad. Sci. USA 94, 2620-2625.
2. AGRAWAL, S., MAYRAND, S.H., ZAMECNIK, P.C., and PEDERSON, T. (1990). Site-specific excision from RNA by RNase H and mixed-phosphate backbone oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 87, 1401-1405.
3. AUGUSTINE, K.A., LIU, E.T., and SADLER, T.W. (1995). Antisense inhibition of engrailed genes in mouse embryos reveals roles for these genes in craniofacial and neural tube development. Teratology 51, 300-310.
4. BELTINGER, C., SARAGOVI, H.U., SMITH, R.M., LESAUTEUR, L., SHAH, N., DEDIONISIO, L., CHRISTENSEN, L., RAIBLE, A., JARETT, L., and GEWIRTZ, A.M. (1995). Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest. 95, 1814-1823.
5. BENNETT, C.F., CHIANG, M.-Y., CHAN, H., SHOEMAKER, J.E.E., and MIRABELLI, C.K. (1992). Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41, 1023-1033.
6. BENNETT, C.F., KORNBRUST, D., HENRY, S., STECKER, K., HOWARD, R., COOPER, S., DUTSON, S., HALL, W., and JACOBY, H.I. (1997). An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J. Pharmacol. Exp. Ther. 280, 988-1000.
7. BERGAN, R., HAKIM, F., SCHWARTZ, G.N., KYLE, E., CEPADA, R., SZABO, J.M., FOWLER, D., GRESS, R., and NECKERS, L. (1996). Electroporation of synthetic oligodeoxynucleotides: A novel technique for ex vivo bone marrow purging. Blood 15, 731-741.
8. COOK, P.D. (1993). Medicinal chemistry strategies for antisense research. In: Antisense Research and Applications. S.T. Cooke, ed. (CRC Press, Boca Raton, FL), pp. 149-188.
9. DAGLE, J.M., WALDER, J.A., and WEEKS, D.L. (1990). Targeted degradation of mRNA in Xenopus oocytes and embryos directed by modified oligonucleotides: Studies of An2 and cyclin in embryogenesis. Nucleic Acids Res. 18, 4751-1757.
10. WILLIAMS, S.A., CHANG, L., BUZBY, J.S., SUEN, Y., and CAIRO, M.S. (1996). Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth. Leukemia 10, 1980-1989.
11. YAZAKI, T., AHMAD, S., CHAHLAVI, A., ZYLBER-KATZ, E., DEN, N.M., RABKIN, S.D., MARTUZA, R.L., and GLAZER, R.I. (1996). Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-α phosphorothioate oligonucleotide. Mol. Pharmacol. 50, 236-242.
12. ZELPHATI, O., and SZOKA, F.C. (1996a). Liposomes as a carrier for intracellular delivery of antisense oligonucleotides: A real or magic bullet? J. Cont. Rel. 41, 99-119.
13. ZELPHATI, O., and SZOKA, F.C. (1996b). Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. USA 93, 11493-11498.